Regional Minister Irujo presents the Navarra Health Cluster

This morning, the Regional Minister for Economic and Business Development, Mikel Irujo, presented the Navarra Health Cluster, seeking to position the region as a European benchmark in personalized medicine, one of the priorities of the S4 Smart Specialisation Strategy. The initiative, which stems from the sector's demand and is led by a driving group, is now open to other companies and entities interested in participating.

3P Biopharmaceuticals (3P), a leading CDMO organization specializing in developing cGMP processes and manufacturing biological products, launches the Navarra Health Cluster together with seven companies in the sector.

The initiative, which stems from the sector’s demand and is led by a driving group, is now open to other companies and entities interested in participating.

This morning, the Regional Minister for Economic and Business Development, Mikel Irujo, presented the Navarra Health Cluster, seeking to position the region as a European benchmark in personalized medicine, one of the priorities of the S4 Smart Specialisation Strategy.

Regional Minister Irujo presents the Navarra Health Cluster

The constitution is being promoted with the support of the Department of Economic and Business Development, aiming to strengthen and increase the sector’s competitiveness. Through measures and lines of impulse and support for competitiveness, from the General Directorates of Business Policy, International Projection and Employment and Industry, Energy and Strategic Projects S4, as well as from Sodena and CEIN, the aim is to promote entrepreneurship, consolidation and business growth.

The initiative is led by eight companies: 3P Biopharmaceuticals, Cinfa, Creo Medical, Idifarma, Innoupfarma, Palo Biofarma, Qubepharma Group and Telum Therapeutics. The process has included numerous driving group working committees meetings to prepare the project. It is now open to other companies and organizations in the sector in Navarre, who are called upon to participate and find a person to manage and promote the project.

Irujo pointed out that “Navarre has a competitive healthcare sector, capable of bringing innovative and accessible solutions to the market for all healthcare challenges. The health sector is key to the economy of Navarre and is also a generator of knowledge, welfare and quality employment”. He also recalled that “Navarre is a pioneer at the national level in the approval of a Comprehensive Strategy for Personalized Medicine, integrating the areas of health, innovation and economic development”, an area that has been supported since 2017 by the R&D calls for strategic projects S4 GEMA (“genomics and advanced medicine”).

Dámaso Molero, CEO of 3P, points out “Our challenges as a region and as a cluster are to bring to the market all these high-quality initiatives in personalized medicine, gene therapy, recombinant proteins, monoclonal antibodies, etc… We must promote science, knowledge and the development of researchers to make Navarre an attractive region and a focus of attention for students and professionals in the sector and their families, scientists, companies, investment funds and investors; that is the great challenge we face”.

Navarra has great strengths in the entire value chain, from scientific production, product development and quality clinical services, a value chain that employs 31,508 people, most of them in healthcare services (27,981), but with 2,465 people working in the healthcare industry and 1,065 in research.

The main industrial area of the health sector is Biopharma, which represents 64% of the industry’s total turnover, with a business fabric comprising of 29 companies that are growing in importance and a turnover of 504 million euros in 2020. The fastest-growing segment in terms of the number of companies is Medical Devices, with 41 companies and a turnover of 60.6 million euros in 2020. Prevention and Wellness is the second most crucial area of the industry linked to Health, with 13 companies representing almost 29% of the total sector turnover of 228.5 million euros. And has opportunities for development and the creation of new initiatives in connection with the healthy eating and personalized nutrition sector.

The turnover of the health sector industry increased by 20.3% in 2020 compared to 2016, which means 134 million euros more turnover, reaching 793 million euros.

View the full press release here

Our dedicated team of specialists will be happy to discuss any of your CDMO supply chain needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN, a leading pan-European biologics CDMO

Published: 1st February 2024
Biovian and 3P Biopharmaceuticals (“3P”), two leading biologics Contract Development and Manufacturing Organizations (CDMOs), announced today their combination to establish a new pan-European leader in their field.
Read more

3P Biopharmaceuticals: building a legacy of innovation and excellence in biotechnology

Published: 20th December 2023
At the International Congress of High Impact Entrepreneurship, orchestrated by the European Business and Innovation Center of Navarra (CEIN), 3P Biopharmaceuticals (3P) emerges as the winner of the "Best Track Record in the CEIN incubators" award
Read more

3P Biopharmaceuticals and the University of Navarra bring the Neanderthal world and biomedicine to the public in a successful event.

Published: 19th October 2023
This afternoon Pamplona became the epicentre of knowledge and innovation in the field of biomedicine, thanks to the event "Exploring our shared legacy between Neanderthals and Sapiens: challenges and uncertainties of future biomedicine", organized by 3P Biopharmaceuticals in collaboration with the Faculty of Pharmacy and Nutrition of the University of Navarra.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.